BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza
CUBIST ANNOUNCES FDA APPROVAL OF NEW ANTIBIOTIC ZERBAXA™ (CEFTOLOZANE/TAZOBACTAM) FOR COMPLICATED URINARY TRACT AND COMPLICATED INTRA-ABDOMINAL INFECTIONS
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting
Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and Separately a 4.8 Log10 Reduction With ACH-3422
REDWOOD CITY, Calif., Dec. 19, 2014 /PRNewswire/ -- Bina Technologies, Inc.
PLEASANTON, Calif., Dec.